EGFR and non-small cell lung carcinoma: The BR.26 trial, a double-blind, placebo-controlled, randomized study, comparing dacomitinib and placebo in patients with advanced NSCLC after standard therapy with both chemotherapy and an EGFR-TKI, also had failed to meet its objective of prolonging OS versus placebo.